32046-84-7

Basic information

• Product Name: 1H-Benzimidazole,5-methyl-4-nitro-(9CI)
• Synonyms: 1H-Benzimidazole,5-methyl-4-nitro-(9CI);6-methyl-7-nitro-1H-Benzimidazole
• CAS NO: 32046-84-7
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16008
• Product Categories: BENZIMIDAZOLE
• Mol File: 32046-84-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole,5-methyl-4-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,5-methyl-4-nitro-(9CI)(32046-84-7)
• EPA Substance Registry System: 1H-Benzimidazole,5-methyl-4-nitro-(9CI)(32046-84-7)

Safety Data

• Hazardous Substances Data: 32046-84-7(Hazardous Substances Data)

Usage

Structure

Benzene ring fused to an imidazole ring

Substituents

A methyl group and a nitro group attached at specific positions

Type of compound

Heterocyclic aromatic organic compound

Usage

Building block in the synthesis of pharmaceuticals and agrochemicals

Reactivity

Versatile

Biological activity

Antimicrobial, anticancer, and antiviral properties

Industrial applications

Production of dyes, pigments, and other chemicals

Importance

Key intermediate in drug discovery and development.

Upstream product

• 614-97-1 5-methylbenzimidazole 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 

Downstream Products

• 317824-83-2 2-[(S)-1-Phenylethylamino]-4-[4-nitro-5-methyl-benzimidazol-1-yl]pyrimidine 
• 935873-39-5 5-methyl-1H-benzo[d]imidazol-4-amine 

Relevant articles and documents

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Src kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.